Beijing Bao Tai: BAT4406F Injection received the approval notice for drug clinical trials.

Bright Tai announcement, recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration regarding the company's investigational drug BAT4406F injection for the indication of minor lesion nephropathy/focal segmental glomerulosclerosis. The drug name is BAT4406F injection, the dosage form is injection, the specification is 100mg/5mL, and the applicant is Bright Tai Biopharmaceutical Co., Ltd. The key registration II/III clinical study results for the indication of spectrum diseases of optic neuritis and myelitis showed that the efficacy met the pre-specified statistical criteria, and the Independent Data Monitoring Committee recommended to "terminate the trial early".